Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wiltschke

Showing results (1-10 of 53) with videos related to

Pageof 6
Sort By:
Acta Medica Austriaca|May 31, 2001
[Tumor markers]W Fiebiger, C Wiltschke
Trends in Endocrinology and Metabolism: TEM|April 1, 1995
Clinical relevance of estrogen receptor variants in breast cancerC Wiltschke, S A Fuqua
Lancet (London, England)|October 26, 1996
99mTc-tetrofosmin soft tissue scanning and metastatic diseaseP Berghammer, C Wiltschke, H Sinzinger, et al.
Journal of the National Cancer Institute|December 31, 1997
Gemcitabine-induced hemolytic uremic syndrome: a case reportT Brodowicz, S Breiteneder, C Wiltschke, et al.
Neoplasma|January 1, 1993
IL-1 alpha induced, TNF alpha mediated HLA class II (DR) antigen up-regulation in a human ductal breast carcinoma cell line ZR-75-1P Speiser, R Zeillinger, C Wiltschke, et al.
American Journal of Clinical Oncology|October 16, 1999
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamideT Brodowicz, W J Köstler, C Wiltschke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trialT Brodowicz, R Kotz, C Wiltschke, et al.
Cancer Detection and Prevention|November 4, 2000
Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequencesW J Köstler, T Brodowicz, M Hejna, et al.
Experimental Hematology|May 1, 1995
Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicityC Wiltschke, M Krainer, A Wagner, et al.
Cancer|October 1, 1992
A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreasW Scheithauer, F Pfeffel, G Kornek, et al.
Pageof 6

Showing results (1-10 of 53) with videos related to

Sort By:
Pageof 6
Acta Medica Austriaca|May 31, 2001
[Tumor markers]W Fiebiger, C Wiltschke
Trends in Endocrinology and Metabolism: TEM|April 1, 1995
Clinical relevance of estrogen receptor variants in breast cancerC Wiltschke, S A Fuqua
Lancet (London, England)|October 26, 1996
99mTc-tetrofosmin soft tissue scanning and metastatic diseaseP Berghammer, C Wiltschke, H Sinzinger, et al.
Journal of the National Cancer Institute|December 31, 1997
Gemcitabine-induced hemolytic uremic syndrome: a case reportT Brodowicz, S Breiteneder, C Wiltschke, et al.
Neoplasma|January 1, 1993
IL-1 alpha induced, TNF alpha mediated HLA class II (DR) antigen up-regulation in a human ductal breast carcinoma cell line ZR-75-1P Speiser, R Zeillinger, C Wiltschke, et al.
American Journal of Clinical Oncology|October 16, 1999
Efficacy of docetaxel in the second-line treatment of locally advanced or metastatic soft tissue sarcoma after failure of chemotherapy with anthracycline or ifosfamideT Brodowicz, W J Köstler, C Wiltschke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trialT Brodowicz, R Kotz, C Wiltschke, et al.
Cancer Detection and Prevention|November 4, 2000
Detection of minimal residual disease in patients with cancer: a review of techniques, clinical implications, and emerging therapeutic consequencesW J Köstler, T Brodowicz, M Hejna, et al.
Experimental Hematology|May 1, 1995
Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicityC Wiltschke, M Krainer, A Wagner, et al.
Cancer|October 1, 1992
A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreasW Scheithauer, F Pfeffel, G Kornek, et al.
Pageof 6